Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the efficacy and safety of the triplet combination of
TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small
cell lung cancer.